X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KNS-760704 (dexpramipexole), a selective inhibitor of eosinophil maturation, in Phase 2 Exhale trial change in FEV1 was correlated with change in blood absolute eosinophil count, demonstrating the link between eosinophil depletion and clinical benefit.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
Avicanna and Knop have developed a collaborative enterprise which has led to commercial imports of Avicanna´s API, including CBD and THC, which has been used in the development, production and commercialization of several cannabinoid-based products.
Lead Product(s): Cannabinoid
Therapeutic Area: Neurology Product Name: Cannabiol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avicanna
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 14, 2022
Details:
The EXHALE trial was a randomized, double-blind, placebo-controlled trial of dexpramipexole in patients with moderate-to-severe asthma and blood absolute eosinophil count (AEC) ≥300/µL.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
Details:
The EXHALE trial was a randomized, double-blind, placebo-controlled study of dexpramipexole in patients with moderate-to-severe asthma and blood absolute eosinophil count (AEC) ≥300/µL.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
In hypereosinophilic syndrome, dexpramipexole has previously been shown in a Phase 2 trial to significantly reduce requirements for oral corticosteroids and in a subset of patients to produce durable disease remission.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
Details:
Primary endpoint was achieved, with dexpramipexole demonstrating a statistically significant reduction in blood eosinophil count over 12 weeks.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Details:
Knopp has developed a discovery platform of molecules directed to a non-opioid biological target linked to chronic pain caused by nerves damage. The drug target is Kv7.2/7.3 which regulates the flow of electrically charged ions required to modulate the excitability of cells.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 08, 2020
Details:
The multi-center Phase 2 trial is a randomized, double-blind, placebo-controlled study to evaluate the effects of three dose levels of oral dexpramipexole for 12 weeks.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
Knopp is advancing the development of KB-3061 as a potential precision medicine for KCNQ2-EE, a rare genetic disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay.
Lead Product(s): KB-3061
Therapeutic Area: Neurology Product Name: KB-3061
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
